Last reviewed · How we verify
metronidazole 500 mg
At a glance
| Generic name | metronidazole 500 mg |
|---|---|
| Also known as | FLAGYL, lysinyl, Metronidazol |
| Sponsor | Freya Biosciences ApS |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease (EARLY_PHASE1)
- Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial (PHASE2)
- Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer (PHASE2)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer (PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- metronidazole 500 mg CI brief — competitive landscape report
- metronidazole 500 mg updates RSS · CI watch RSS
- Freya Biosciences ApS portfolio CI